2014 – Blog Posts Of The Year

16/01/2015

It’s already the middle of January, so before the new year steadily sets in, we’d like to have a quick look back on the route we just came, not long ago. Omixon had an amazing and very successful 2014. We launched our brand new product Holotype HLA™, opened first offices in...

Immunotherapy

07/01/2015

Cancer has become one of the biggest killers in the western world. High profile campaigns to tackle breast cancer and other common types have ensured that it is also one of the biggest businesses in modern medicine. To fight a high profile killer you need the best of cures....

Webinar – Rare & Null Allele Detection with HLA Twin™

04/12/2014

Are you interested in Orthogonal Bioinformatic Validation? Watch this latest webinar presentation on HLA Twin™ – Rare & Null Allele Detection Date: Thursday, 11th December, 2014 Time: 12:00–1pm EST (6–7pm CET) A live Q&A session will follow the presentation, offering you the opportunity to put forward any questions. Following registration, you...

Patient Stratification in Clinical Trials

01/12/2014

When carrying out clinical trials, one of the most important logistical and statistical challenges is ensuring that your data accurately reflects the population you are setting out to study. None of us has the resources to test a drug on the entire human race, but if we want to...

Omixon Signs Letter of Intent with Pronto Diagnostics

10/11/2014

At Omixon we are working hard to expand our customer base. Our Holotype HLA kit is already making an impact on the HLA typing market, and we are regularly contacted by companies proposing to partner with us as local distributors. For example, we have recently signed a letter of intent with Pronto...